Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

Exclusion Criteria

• •1. Aflibercept injections with unspecified laterality will be excluded
• •2. Aflibercept injections from individuals aged \<18 years or those with unknown age on the injection date will be excluded
• •3. Patient-eyes with a diagnosis of RV in the same eye as the aflibercept injection or with unspecified laterality within 12 months (365 days) prior to index date (inclusive), as defined in the protocol
• •4. Patient-eyes that do not meet the continuous enrollment requirement will be excluded
• •5. Aflibercept injections will be excluded if there is ≥1 other anti-VEGF injection administered on the same date